Cat. # | Size | Qty. | Price |
---|---|---|---|
48160S | 100 µl |
|
REACTIVITY | M |
SENSITIVITY | Endogenous |
MW (kDa) | 280 |
Source/Isotype | Mouse IgG1 kappa |
Product Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Immunoprecipitation | 1:100 |
For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
NOTE: Please refer to primary antibody product webpage for recommended antibody dilution.
NOTE: Prepare solutions with reverse osmosis deionized (RODI) or equivalent grade water.
Load 20 µl onto a 3-8% Tris-Acetate, SDS-PAGE gel (8 cm x 13 cm), using 1X Tris-Acetate SDS Running Buffer.
NOTE: Loading of prestained molecular weight markers (#12949, 10 µl/lane) to verify electrotransfer and biotinylated protein ladder (#7727, 10 µl/lane) to determine molecular weights are recommended.
NOTE: Volumes are for 10 cm x 10 cm (100 cm2) of membrane; for different sized membranes, adjust volumes accordingly.
* Avoid repeated exposure to skin.
Protocol Id: 2884
This protocol is intended for immunoprecipitation of native proteins utilizing Protein G agarose beads for subsequent analysis by western immunoblot or kinase activity.
NOTE: Prepare solutions with reverse osmosis deionized (RODI) or equivalent grade water.
10X Cell Lysis Buffer: (#9803) To prepare 10 ml of 1X cell lysis buffer, add 1 ml cell lysis buffer to 9 ml dH2O, mix.
NOTE: Add 1 mM PMSF (#8553) immediately prior to use.
IMPORTANT: Appropriate isotype controls are highly recommended in order to show specific binding in your primary antibody immunoprecipitation. Use Normal Rabbit IgG #2729 for rabbit polyclonal primary antibodies, Rabbit (DA1E) mAb IgG XP® Isotype Control #3900 for rabbit monoclonal primary antibodies, Mouse (G3A1) mAb IgG1 Isotype Control #5415 for mouse monoclonal IgG1 primary antibodies, Mouse (E5Y6Q) mAb IgG2a Isotype Control #61656 for mouse monoclonal IgG2a primary antibodies, Mouse (E7Q5L) mAb IgG2b Isotype Control #53484 for mouse monoclonal IgG2b primary antibodies, and Mouse (E1D5H) mAb IgG3 Isotype Control #37988 for mouse monoclonal IgG3 primary antibodies. Isotype controls should be concentration matched and run alongside the primary antibody samples.
Proceed to one of the following specific set of steps.
NOTE: When using primary antibodies produced in rabbit to to detect proteins with a molecular weight in the range of 50 kDa, we recommend using Mouse Anti-Rabbit IgG (Light-Chain Specific) (D4W3E) mAb (#45262) or Mouse Anti-Rabbit IgG (Conformation Specific) (L27A9) mAb (#3678) (or HRP conjugate #5127) as a secondary antibody to minimize interference produced by denatured rabbit heavy chain. For proteins with a molecular weight in the range of 25 kDa, Mouse Anti-Rabbit IgG (Conformation Specific) (L27A9) mAb (#3678) (or HRP conjugate #5127) is recommended to minimize interference produced by denatured mouse heavy or light chain.
When using primary antibodies produced in mouse to detect proteins with a molecular weight in the range of 50 kDa, we recommend using Rabbit Anti-Mouse IgG (Light Chain Specific) (D3V2A) mAb (HRP Conjugate) (#58802) as a secondary antibody to minimize interference produced by denatured mouse heavy chain.
posted October 2016
revised October 2021
Protocol Id: 1244
Mouse
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the carboxy terminus of human POLQ protein.
Mammalian cells undergo DNA damage in response to various intrinsic and extrinsic forces, and signaling pathways are in place to sense and repair damaged DNA to avoid genome instability and mutation. Repair of toxic DNA double-strand breaks (DSBs) can occur through several pathways, and pathway choice may depend on the cell cycle phase and the nature of the DSB (1). The two main pathways for DSB repair are classical non-homologous end joining (C-NHEJ) and homologous recombination (HR). In addition, three error-prone pathways, single-strand annealing (SSA), microhomology-mediated end-joining (MMEJ), and polymerase theta-mediated end-joining (TMEJ) have been described (2).
Exploiting DNA repair deficiencies in human cancer by targeting intact DNA repair pathways is a promising approach to cancer therapy. This approach has been successful with the use of poly (ADP-ribose) polymerase (PARP) inhibitors in HR-deficient cancer (3).DNA polymerase θ, encoded by the POLQ gene, is a 290 kDa protein with an N-terminal helicase-like domain and a C-terminal DNA polymerase domain (4). ZEB1, an epithelial-mesenchymal transition (EMT) transcription factor, has been shown to regulate TMEJ by suppressing POLQ expression (5). DNA polymerase θ is essential in TMEJ and is, therefore, an important target for drug development in HR-deficient cancers (6,7). Several inhibitors of DNA polymerase θ are under investigation in pre-clinical and clinical trials (8,9).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.